Jennifer Cochran
#153,008
Most Influential Person Now
Professor of bioengineering and researcher in biophysics, cancer biology, and immunology
Jennifer Cochran's AcademicInfluence.com Rankings
Jennifer Cochranengineering Degrees
Engineering
#7837
World Rank
#9272
Historical Rank
Bioengineering
#95
World Rank
#97
Historical Rank
Applied Physics
#3150
World Rank
#3224
Historical Rank
Download Badge
Engineering
Jennifer Cochran's Degrees
- PhD Bioengineering University of California, Berkeley
Why Is Jennifer Cochran Influential?
(Suggest an Edit or Addition)According to Wikipedia, Jennifer R. Cochran is an American bioegineer. Cochran completed a bachelor's degree in biochemistry at the University of Delaware in 1995, and pursued doctoral study in biological chemistry at the Massachusetts Institute of Technology. After graduating in 2001, she remained at MIT as a postdoctoral fellow. Cochran later joined the Stanford University faculty, where she was named Shriram Chair of the Department of Bioengineering. She was elected a fellow of the American Institute for Medical and Biological Engineering in 2018.
Jennifer Cochran's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Flow-cytometric isolation of human antibodies from a nonimmune Saccharomyces cerevisiae surface display library (2003) (476)
- Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses (2016) (379)
- Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome (2020) (345)
- The relationship of MHC-peptide binding and T cell activation probed using chemically defined MHC class II oligomers. (2000) (262)
- Engineering growth factors for regenerative medicine applications. (2016) (228)
- Targeted Contrast-Enhanced Ultrasound Imaging of Tumor Angiogenesis with Contrast Microbubbles Conjugated to Integrin-Binding Knottin Peptides (2010) (154)
- Applications of Yeast Surface Display for Protein Engineering. (2015) (148)
- Engineered knottin peptides: a new class of agents for imaging integrin expression in living subjects. (2009) (142)
- Engineered cystine knot peptides that bind αvβ3, αvβ5, and α5β1 integrins with low‐nanomolar affinity (2009) (132)
- Fine epitope mapping of anti-epidermal growth factor receptor antibodies through random mutagenesis and yeast surface display. (2004) (125)
- Measurements of translation initiation from all 64 codons in E. coli (2016) (124)
- Identification of the Epitope for the Epidermal Growth Factor Receptor-specific Monoclonal Antibody 806 Reveals That It Preferentially Recognizes an Untethered Form of the Receptor* (2004) (124)
- Emerging Strategies for Developing Next-Generation Protein Therapeutics for Cancer Treatment. (2016) (117)
- An engineered Axl 'decoy receptor' effectively silences the Gas6-Axl signaling axis. (2014) (107)
- Engineered cystine-knot peptides that bind alpha(v)beta(3) integrin with antibody-like affinities. (2009) (105)
- Development of Hydrogel‐Based Keratoprostheses: A Materials Perspective (2008) (101)
- Design and fabrication of an artificial cornea based on a photolithographically patterned hydrogel construct (2007) (99)
- LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation (2021) (95)
- Cutting Edge: Detection of Antigen-Specific CD4+ T Cells by HLA-DR1 Oligomers Is Dependent on the T Cell Activation State1 (2001) (93)
- Domain-level antibody epitope mapping through yeast surface display of epidermal growth factor receptor fragments. (2004) (86)
- High-throughput screening technologies for enzyme engineering. (2017) (84)
- Delivery of an engineered HGF fragment in an extracellular matrix-derived hydrogel prevents negative LV remodeling post-myocardial infarction. (2015) (84)
- Novel NanoLuc substrates enable bright two-population bioluminescence imaging in animals (2020) (78)
- Inhibition of the GAS6/AXL pathway augments the efficacy of chemotherapies (2017) (77)
- High-throughput analysis and protein engineering using microcapillary arrays (2015) (77)
- Engineered knottin peptides as diagnostics, therapeutics, and drug delivery vehicles. (2016) (76)
- Soluble peptide–MHC monomers cause activation of CD8+ T cells through transfer of the peptide to T cell MHC molecules (2002) (75)
- Directed evolution of the epidermal growth factor receptor extracellular domain for expression in yeast (2005) (74)
- Receptor clustering and transmembrane signaling in T cells. (2001) (72)
- Antibodies specifically targeting a locally misfolded region of tumor associated EGFR (2009) (66)
- Receptor Proximity, Not Intermolecular Orientation, Is Critical for Triggering T-cell Activation* (2001) (64)
- Improved mutants from directed evolution are biased to orthologous substitutions. (2006) (63)
- Engineered knottin peptide enables noninvasive optical imaging of intracranial medulloblastoma (2013) (58)
- Bioactive interpenetrating polymer network hydrogels that support corneal epithelial wound healing. (2009) (58)
- Evaluation of a 64Cu-Labeled Cystine-Knot Peptide Based on Agouti-Related Protein for PET of Tumors Expressing αvβ3 Integrin (2010) (57)
- A dual-labeled knottin peptide for PET and near-infrared fluorescence imaging of integrin expression in living subjects. (2010) (57)
- In Vivo Site-Specific Protein Tagging with Diverse Amines Using an Engineered Sortase Variant. (2016) (53)
- An engineered knottin peptide labeled with 18F for PET imaging of integrin expression. (2009) (52)
- Antagonistic VEGF variants engineered to simultaneously bind to and inhibit VEGFR2 and αvβ3 integrin (2011) (52)
- Engineering knottins as novel binding agents. (2012) (51)
- Integrin-Targeting Knottin Peptide-Drug Conjugates Are Potent Inhibitors of Tumor Cell Proliferation. (2016) (49)
- A diverse set of oligomeric class II MHC-peptide complexes for probing T-cell receptor interactions. (2000) (48)
- T-cell activation by soluble MHC oligomers can be described by a two-parameter binding model. (2001) (47)
- Anti-GD2 synergizes with CD47 blockade to mediate tumor eradication (2022) (47)
- Engineering hepatocyte growth factor fragments with high stability and activity as Met receptor agonists and antagonists (2011) (47)
- PET imaging of tumor neovascularization in a transgenic mouse model with a novel 64Cu-DOTA-knottin peptide. (2010) (44)
- Engineering Agatoxin, a Cystine-Knot Peptide from Spider Venom, as a Molecular Probe for In Vivo Tumor Imaging (2013) (42)
- CAR T-cell immunotherapy of MET-expressing malignant mesothelioma (2017) (42)
- Functional Mutation of Multiple Solvent-Exposed Loops in the Ecballium elaterium Trypsin Inhibitor-II Cystine Knot Miniprotein (2011) (42)
- Beyond antibodies: using biological principles to guide the development of next-generation protein therapeutics. (2013) (42)
- Toward the development of an artificial cornea: improved stability of interpenetrating polymer networks. (2011) (40)
- Cystine-knot peptides: emerging tools for cancer imaging and therapy (2014) (39)
- Structure and Functional Binding Epitope of V-domain Ig Suppressor of T Cell Activation. (2019) (39)
- Cystine‐knot peptides engineered with specificities for αIIbβ3 or αIIbβ3 and αvβ3 integrins are potent inhibitors of platelet aggregation (2011) (37)
- Cell-Binding Assays for Determining the Affinity of Protein-Protein Interactions: Technologies and Considerations. (2016) (36)
- Developing therapeutic proteins by engineering ligand-receptor interactions. (2008) (36)
- Enhanced safety and efficacy of protease-regulated CAR-T cell receptors (2022) (35)
- SARS-CoV-2 Antibody Responses Correlate with Resolution of RNAemia But Are Short-Lived in Patients with Mild Illness (2020) (34)
- Antitumor activity of an engineered decoy receptor targeting CLCF1–CNTFR signaling in lung adenocarcinoma (2019) (34)
- Biocompatibility of poly(ethylene glycol) and poly(acrylic acid) interpenetrating network hydrogel by intrastromal implantation in rabbit cornea. (2015) (33)
- Integrin-targeted cancer immunotherapy elicits protective adaptive immune responses (2017) (33)
- Interrogating and Predicting Tolerated Sequence Diversity in Protein Folds: Application to E. elaterium Trypsin Inhibitor-II Cystine-Knot Miniprotein (2009) (30)
- A Chemically Cross-Linked Knottin Dimer Binds Integrins with Picomolar Affinity and Inhibits Tumor Cell Migration and Proliferation (2014) (30)
- Targeting ligand-receptor interactions for development of cancer therapeutics. (2017) (29)
- Preliminary evaluation of 177Lu-labeled knottin peptides for integrin receptor-targeted radionuclide therapy (2011) (29)
- PET Imaging of Integrin Positive Tumors Using 18F Labeled Knottin Peptides (2011) (28)
- Interpenetrating polymer network hydrogel scaffolds for artificial cornea periphery (2015) (27)
- A novel protein‐engineered hepatocyte growth factor analog released via a shear‐thinning injectable hydrogel enhances post‐infarction ventricular function (2017) (26)
- Targeted Drug Delivery with an Integrin-Binding Knottin–Fc–MMAF Conjugate Produced by Cell-Free Protein Synthesis (2016) (26)
- Degradable acetalated dextran microparticles for tunable release of an engineered hepatocyte growth factor fragment. (2016) (25)
- Delivery of CAR-T cells in a transient injectable stimulatory hydrogel niche improves treatment of solid tumors (2021) (25)
- Targeting of Cancer Cells Using Quantum Dot–Polypeptide Hybrid Assemblies That Function as Molecular Imaging Agents and Carrier Systems (2010) (24)
- Multi-phase catheter-injectable hydrogel enables dual-stage protein-engineered cytokine release to mitigate adverse left ventricular remodeling following myocardial infarction in a small animal model and a large animal model. (2020) (23)
- Engineered Proteins Pull Double Duty (2010) (23)
- Engineered epidermal growth factor mutants with faster binding on‐rates correlate with enhanced receptor activation (2011) (22)
- An engineered antibody binds a distinct epitope and is a potent inhibitor of murine and human VISTA (2020) (22)
- Heterogeneous delivery across the blood-brain barrier limits the efficacy of an EGFR-targeting antibody drug conjugate in glioblastoma. (2021) (21)
- An engineered dimeric fragment of hepatocyte growth factor is a potent c‐MET agonist (2014) (20)
- Elucidation of the interleukin-15 binding site on its alpha receptor by NMR. (2007) (19)
- 111In-Labeled Cystine-Knot Peptides Based on the Agouti-Related Protein for Targeting Tumor Angiogenesis (2012) (19)
- Dual display of proteins on the yeast cell surface simplifies quantification of binding interactions and enzymatic bioconjugation reactions. (2017) (18)
- Collins Asymmetries in Inclusive Charged KK and Kπ Pairs Produced in e⁺e⁻ Annihilation (2015) (16)
- Measurement of W+W-production in association with one jet in proton-proton collisions at √s = 8 TeV with the ATLAS detector (2016) (15)
- Development of a Protease Biosensor Based on a Dimerization-Dependent Red Fluorescent Protein. (2017) (14)
- PET Reporter Gene Imaging and Ganciclovir-Mediated Ablation of Chimeric Antigen Receptor T Cells in Solid Tumors (2020) (14)
- Engineering a potent receptor superagonist or antagonist from a novel IL-6 family cytokine ligand (2020) (13)
- Diffusion of Protein through the Human Cornea (2009) (13)
- Discovery of improved EGF agonists using a novel in vitro screening platform. (2011) (12)
- Measurement of the D*(2010)(+) natural linewidth and the D*(2010)(+)-D-0 mass difference (2013) (12)
- A novel radiofluorinated agouti-related protein for tumor angiogenesis imaging (2013) (11)
- Broad-spectrum CRISPR-mediated inhibition of SARS-CoV-2 variants and endemic coronaviruses in vitro (2022) (11)
- Neutralizing antibodies targeting the SARS‐CoV‐2 receptor binding domain isolated from a naïve human antibody library (2021) (11)
- Cell Surface Display Systems For Protein Engineering (2009) (11)
- Heterochiral Knottin Protein: Folding and Solution Structure. (2017) (10)
- An engineered ligand trap inhibits leukemia inhibitory factor as pancreatic cancer treatment strategy (2021) (9)
- Phage display and molecular imaging: expanding fields of vision in living subjects (2010) (9)
- Structural basis of the differential binding of engineered knottins to integrins αVβ3 and α5β1 (2019) (9)
- Engineering High Affinity Protein-Protein Interactions Using a High-Throughput Microcapillary Array Platform. (2017) (9)
- CD52 Is Elevated on B cells of SLE Patients and Regulates B Cell Function (2021) (8)
- Engineered ligand‐based VEGFR antagonists with increased receptor binding affinity more effectively inhibit angiogenesis (2017) (7)
- Systemic delivery of a targeted synthetic immunostimulant transforms the immune landscape for effective tumor regression. (2021) (6)
- Neutralizing antibodies targeting the SARS-CoV-2 receptor binding domain isolated from a naïve human antibody library (2021) (6)
- Structure and Functional Binding Epitope of V-domain Ig Suppressor of T-cell Activation (VISTA) (2019) (6)
- Use of Outpatient-Derived COVID-19 Convalescent Plasma in COVID-19 Patients Before Seroconversion (2021) (5)
- Lysosome Targeting Chimeras (LYTACs) That Engage a Liver-Specific Asialoglycoprotein Receptor for Targeted Protein Degradation (2020) (4)
- Engineering a potent inhibitor of matriptase from the natural hepatocyte growth factor activator inhibitor type-1 (HAI-1) protein (2018) (3)
- TCR: losing its inhibitions? (2001) (3)
- Development of a Novel Keratoprosthesis Based on Photolithographically Patterned, Biomimetic Hydrogels (2007) (2)
- Anti-GD2 antibody disrupts GD2:Siglec-7 interactions and synergizes with CD47 blockade to mediate tumor eradication (2021) (2)
- EXPERIMENTAL THERAPEUTICS AND PHARMACOLOGY (2013) (2)
- Identification of N-Terminally Diversified GLP-1R Agonists Using Saturation Mutagenesis and Chemical Design. (2020) (2)
- A Bioengineered Peptide that Localizes to and Illuminates Medulloblastoma: A New Tool with Potential for Fluorescence-Guided Surgical Resection (2014) (1)
- Mutational screens highlight glycosylation as a modulator of colony-stimulating factor 3 receptor (CSF3R) activity. (2023) (0)
- High-affinity AXL decoy receptor (2017) (0)
- Antitumor activity of an engineered decoy receptor targeting CLCF1–CNTFR signaling in lung adenocarcinoma (2019) (0)
- CILIARY NEUROTROPHIC FACTOR RECEPTOR LIGANDS AND METHODS OF USING THE SAME (2018) (0)
- Cancer esearch rated Systems and Technologies Imaging of Tumor Neovascularization in a Transgenic R se Model with a Novel 64 Cu-DOTA-Knottin Peptide (2010) (0)
- Structural Basis of the Differential Binding of Engineered Knottins to Integrins alpha V beta 3 and alpha 5 beta 1. (2019) (0)
- 4.412 – Rational and Combinatorial Methods to Create Designer Protein Interfaces (2011) (0)
- 768 Systemic delivery of a tumor-targeted TLR9 agonist conjugate transforms the tumor immune landscape and induces tumor regression in mice (2021) (0)
- An 18F-labeled Agouti-related protein for PET imaging of integrin positive tumor (2011) (0)
- Photoactive Split Green Fluorescent Protein: Engineering a New Optogenetic and Imaging System (2018) (0)
- Dependent on the T Cell Activation State T Cells by HLA-DR1 Oligomers Is + CD4Cutting Edge: Detection of Antigen-Specific (2000) (0)
- Imaging Integrin Expression in Living Subjects Engineered Knottin Peptides : A New Class of Agents for (2009) (0)
- Solution NMR Structure of Engineered Cystine Knot Protein 2.5F (2014) (0)
- Mutational screens highlight glycosylation as a modulator of CSF3R activity (2022) (0)
- Sequential Coupling of Epidermal Growth Factor and Collagen to Polymers to Promote Corneal Epithelialization in vitro (2008) (0)
- Engineered ligand and receptor based fusion proteins as next generation cancer therapeutics (2017) (0)
- A novel radiofluorinated agouti-related protein for tumor angiogenesis imaging (2012) (0)
- Surface Modification of High-Strength Interpenetrating Network Hydrogels for Biomedical Device Applications (2013) (0)
- Crystal structure of human VISTA extracellular domain (2019) (0)
- Novel NanoLuc substrates enable bright two-population bioluminescence imaging in animals (2020) (0)
- Letters to Nature 808 (0)
- Engineering Epidermal Growth Factor Mutant Proteins for Wound Healing (2007) (0)
- eveloping therapeutic proteins by ngineering ligand – receptor nteractions (2008) (0)
- Issue information (2021) (0)
- Corrigendum to: “Fine Epitope Mapping of anti-Epidermal Growth Factor Receptor Antibodies Through Random Mutagenesis and Yeast Surface Display” [J. Mol. Biol. (2004) 342, 539–550] (2005) (0)
- Long-Term Biocompatibility of PEG/PAA Hydrogel by Intrastromal Implantation in Rabbit Cornea (2010) (0)
- Abstract 5741: Harnessing macrophages, while protecting T cells, enhances anti-tumor efficacy (2023) (0)
- In vivo evaluation of melanoma targeted multivalent {alpha}-melanocyte-stimulating hormone analogs using microPET studies (2009) (0)
This paper list is powered by the following services:
Other Resources About Jennifer Cochran
What Schools Are Affiliated With Jennifer Cochran?
Jennifer Cochran is affiliated with the following schools:
